104 results
424B3
RGBP
Regen BioPharma Inc
24 Apr 24
Prospectus supplement
1:28pm
the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference … between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which
424B3
RGBP
Regen BioPharma Inc
19 Jan 24
Prospectus supplement
1:29pm
by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting … and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse
424B3
RGBP
Regen BioPharma Inc
20 Nov 23
Prospectus supplement
9:38am
another marketing application for the same drug for that time period. The sponsor of the product would also be entitled to a United States federal tax … States federal tax credit equal to 50% of clinical investigation expenses as well as exemptions from certain fees.
The Company believes
424B3
89e9hf
2 Oct 23
Prospectus supplement
1:42pm
8-K
EX-10.1
omevsvuq vyndzi
18 Sep 23
Entry into a Material Definitive Agreement
4:02pm
8-K
EX-10.2
54m5hnz882
18 Sep 23
Entry into a Material Definitive Agreement
4:02pm
8-K
EX-10.3
23h7qfv6n
18 Sep 23
Entry into a Material Definitive Agreement
4:02pm
424B3
xz8x4i
15 May 23
Prospectus supplement
10:25am